title: One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome.
abstract: OBJECTIVE
  One hundred autotransplants for Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) were examined prospectively to identify variables with prognostic significance.
  
  
  METHODS
  Ninety-six patients with relapsed or refractory HD or NHL underwent 100 autotransplants. Patients received high-dose carmustine (BCNU), etoposide, cytarabine, and cyclophosphamide (BEAC) followed by unpurged autologous stem-cell rescue.
  
  
  RESULTS
  The 3-year actuarial event-free survival (EFS) rate for the 47 HD patients is 49%, with a median followup duration of 2 years. For the 53 NHL patients, the 3-year actuarial EFS rate is 40%, with a median follow-up duration of 19 months. By multivariate analysis, minimal disease on admission (all areas < or = 2 cm) is associated with improved EFS (HD, P = .003, NHL, P = .03). The projected EFS rate for HD patients entering with minimal disease is 70% versus 15% for patients with bulky disease (P = .0001). The projected EFS rate for NHL patients with minimal disease is 48% versus 25% for patients with bulky disease (P = .04). Posttransplant involved-field radiotherapy, administered to 26 of the last 61 patients, was associated with an improved EFS rate for NHL patients (P = .015). The BEAC regimen was well tolerated by patients who entered the study with minimal disease (mortality rate, < 5%), but caused significant toxicity in patients with bulky disease (mortality rate, 25%).
  
  
  CONCLUSIONS
  Disease burden before autotransplantation is an important predictor of regimen-related toxicity and EFS. Posttransplant involved-field radiotherapy may improve outcomes in select patients with NHL. The BEAC regimen is safe and effective, particularly for patients with minimal disease.
authors.affiliation: University of Rochester Medical Center, NY.
authors.forename: A P
authors.initials: AP
authors.lastname: Rapoport
authors.forename: J M
authors.initials: JM
authors.lastname: Rowe
authors.forename: P A
authors.initials: PA
authors.lastname: Kouides
authors.forename: R A
authors.initials: RA
authors.lastname: Duerst
authors.forename: C N
authors.initials: CN
authors.lastname: Abboud
authors.forename: J L
authors.initials: JL
authors.lastname: Liesveld
authors.forename: C H
authors.initials: CH
authors.lastname: Packman
authors.forename: S
authors.initials: S
authors.lastname: Eberly
authors.forename: M
authors.initials: M
authors.lastname: Sherman
authors.forename: M A
authors.initials: MA
authors.lastname: Tanner
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012008:Recurrence; D012720:Severity of Illness Index; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D016896:Treatment Outcome